May 01, 2026 a 01:00 pm
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals offers promising advancements in cystic fibrosis treatments, making significant strides within the biopharmaceutical sector. With a diversified pipeline and strong partnerships, VRTX continues to show potential for growth, though investors should consider market volatility. Improved revenue streams from key therapies indicate a solid position for future developments.
Fundamental Rating
Vertex Pharmaceuticals presents a solid fundamental profile with a 'B+' rating reflecting balanced strengths across key financial metrics.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
Recent historical ratings indicate stable general financial health with consistent evaluation over the past reports.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-30 | 3 | 4 | 5 | 5 | 2 | 2 | 1 |
| [Past Date] | 0 | 4 | 5 | 5 | 2 | 2 | 1 |
Analyst Price Targets
Analyst targets indicate a positive outlook, with a consensus suggesting potential for upward movement.
| High | Low | Median | Consensus |
|---|---|---|---|
| 612 | 437 | 558 | 552.27 |
Analyst Sentiment
Overall analyst sentiment is bullish, with a majority recommending buys and no strong sells.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 48 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals presents investors with a robust opportunity in the biopharmaceutical sector, driven by its leadership in cystic fibrosis treatments and an encouraging development pipeline. While its financial metrics highlight certain areas for improvement, analyst sentiment remains predominantly positive, suggesting potential for market success. However, investors should remain cautious of regulatory risks and competition within biotech. Overall, VRTX holds promise, contingent on pipeline approvals and successful market adaptations.